SC: Confirmation of an Auction Sale Does Not Bar Judicial Scrutiny of Reserve Price Valuation  ||  Supreme Court Sets Aside Conviction of Four Men in a 1998 Gang Rape Case  ||  Supreme Court: Privy Purse Privileges of Princely Rulers are Not Enforceable Legal Rights  ||  Delhi HC: Repeated Court Summons May Distress and Re-Traumatize Child Sexual Assault Victims  ||  Jammu and Kashmir High Court: Labeling Someone as a Terrorist Associate Amounts to Defamation  ||  Delhi HC: Setting Aside or Altering a Judge’s Order by a Higher Court Doesn’t Affect Their Integrity  ||  Delhi High Court: Accused Cannot be Faulted For Smart Replies; Interrogator Must be Sharper  ||  Supreme Court: Belated Jurisdictional Challenge Impermissible After Participation in Arbitration  ||  Supreme Court: Failure to Prove Specific Overt Acts of Each Unlawful Assembly Member Not Fatal  ||  Supreme Court: Parental Salary Alone Cannot Determine OBC Creamy Layer Status    

Why drugs are being taken off pharmacy shelves - (21 Mar 2016)

Civil

Headlines in recent days and weeks have reported hundreds, even thousands of drugs being banned from sale in India. Pharmacists are warning of shortages, a kinder way of saying rising prices, while also informing the Drug Controller General of India of the heightening probability of closure of shops, a.k.a., a strike. But why the sudden onset hostility towards certain medicines?

The banning of drugs may seem to have sprung out of the blue but there is method in the pharmacophobia. Circa June of 2013, the Directorate General of Health Services, under the auspices of the Ministry of Health and Family Welfare, released a report, ‘Policy Guidelines for Approval of Fixed Dose Combinations (FDCs) in India’. Prepared under the aegis of Professor C.K. Kokate, the Report considered the prevalence of ‘Fixed Dose Combination’, drugs comprising two or more active ingredients in a fixed ratio. The rationale behind FDCs is simple: two or more ‘actives’ that complement each other or provide the benefit of two products in one swallowing. But, to ensure FDCs’ benefits outweighing their risks, the Report called for called such preparations being based on “convincing therapeutic rationalization and be carefully justified and clinically relevant.” Categories of FDCs were penned and the onus was on manufacturers to show the rationale behind having two or more active ingredients in one preparation.

The Report birthed the ‘Kokate Committee’: tasked with the implementation of recommendations in the report, the Committee has spent over one year perusing thousands of drugs. As of January 2015, the Committee had found only 42.07 per cent of FDCs submitted for perusal as rational, and over 30 per cent as requiring further data or deliberation.

Tags : MINISTRY OF HEALTH   FIXED DOSE COMBINATIONS   RATIONALE  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved